2024-519024-25-00
Not yet recruiting
Phase 2
Faecal Bacteriotherapy for Postantibiotic Diarrhoea in Critically Ill Patients – Randomised Controlled Trial
Fakultni Nemocnice Kralovske Vinohrady1 site in 1 country36 target enrollmentStarted: December 3, 2024Last updated:
Overview
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Fakultni Nemocnice Kralovske Vinohrady
- Enrollment
- 36
- Locations
- 1
- Primary Endpoint
- Percentage of patients with treatment failure at day 7 after randomisation.
Overview
Brief Summary
Percentage of patients with treatment failure at day 7 after randomisation. Treatment failure is defined as either failure to administer allocated treatment for any reason or the presence of diarrhoea on day 7 after randomisation.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Signed informed consent
- •Age > 18 yrs.
- •In-patient in ICU or HDU (incl. burn unit) and expected to stay for >7 days
- •Diarrhoea following antibiotic treatment defined as 3 or more stools per day or Bristol type 7 stool in the volume >300 ml/day if stool derivative device is in place, persisting for 24 hours despite enteral feeding formula has been stopped
Exclusion Criteria
- •Death appears imminent or ceilings of care put in place, presence of new-onset sepsis defined as per 2016 definition, lactate >2.0 mM, colon diameter > 9 cm on plain AXR, the necessity of ongoing antibiotic treatment for another reasons.
- •Unable to tolerate enema for any reason (e.g. surgery of the GI tract in the past year).
- •Pregnant and lactating woman
- •Patients with a history of severe anaphylactic food allergy, any other reason which – as per judgement of the treating clinician – makes faecal transplantation unsafe or not feasible
Outcomes
Primary Outcomes
Percentage of patients with treatment failure at day 7 after randomisation.
Percentage of patients with treatment failure at day 7 after randomisation.
Secondary Outcomes
- Composite number of adverse events such as new-onset sepsis, toxic mega-colon, positive post FBT blood culture, or other SAE assessed by the physi-cian-in-charge as possibly related to FBT.
- SOFA score at days 4 and 7.
- Percentage of patients that are recurrence-free at time of hospital discharge or day 28, whichever occur earlier.
- Subgroup analysis will be performed for patients who are C. dif. positive vs. negative and those who will receive antibiotics for a new extraabdominal in-fection vs. those who do not.
Investigators
Dr Frantisek Duska, PhD
Scientific
Fakultni Nemocnice Kralovske Vinohrady
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 4
Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis.2023-508441-41-00Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla306
Recruiting
Phase 4
Efficacy of 7 days versus 14 days of antibiotic therapy for acute pyelonephritis in kidney transplant recipients2024-513328-40-00Assistance Publique Hopitaux De Paris, Assistance Publique Hopitaux De Paris470
Recruiting
Not Applicable
Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety StatisticsNCT07261826Chen QiYi4,000
Recruiting
Phase 4
A trial to compare efficacy and tolerability of Plenvu® and Picoprep® as cleansing agents of the large bowel before colonoscopy (examination of
the bowel with a fiberoptic device)2024-518544-21-00Aalborg University Hospital400
Not yet recruiting
Phase 4
Comparison of continuing intravenous antibiotic therapy with switching to oral antibiotics in clinically stable patients with blood infections caused by Gram-negative bacteria (INVEST study)2024-517308-13-00Tan Tock Seng Hospital Pte. Ltd.150